Filtered By:
Condition: Bleeding
Countries: Thailand Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 10 results found since Jan 2013.

Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry
CONCLUSION: This Win Ratio analysis demonstrates the significant benefits of NOACs over warfarin and ABC pathway adherence over nonadherence in reducing the composite outcome in patients with AF.PMID:37625457 | DOI:10.1055/s-0043-1772773
Source: Thrombosis and Haemostasis - August 25, 2023 Category: Hematology Authors: Sukrit Treewaree Gregory Y H Lip Rungroj Krittayaphong Source Type: research

Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study
Conclusion: In real practice, ticagrelor swi tching among patients with STE-ACS post streptokinase therapy did not differ regarding safety outcomes and composite of efficacy outcomes compared with clopidogrel.
Source: PLoS One - August 4, 2023 Category: Biomedical Science Authors: Phornpaka Ueapornpanith Source Type: research

Causes of death of patients with non-valvular atrial fibrillation in Asians
ConclusionDeath due to ischemic stroke was responsible for only 4.7% of all deaths in Asian AF patients. Non-CV death, such as infection/sepsis or malignancy, was more far more prevalent than CV death in Asian AF patients. An improved integrated care approach is needed to reduce the prevalence of non-CV death in Asian AF patients.
Source: PLoS One - March 1, 2023 Category: Biomedical Science Authors: Rungroj Krittayaphong Source Type: research

Outcome disparities in patients with atrial fibrillation based on insurance plan and educational attainment: a nationwide, multicenter and prospective cohort trial
Conclusion Educational attainment was independently associated with all-cause mortality and ischaemic stroke in patients with AF, but adverse clinical outcomes were not related to the types of health insurance in Thailand. Trial registration number Thai Clinical Trial Registration; Study ID: TCTR20160113002.
Source: BMJ Open - August 10, 2022 Category: General Medicine Authors: Apiyasawat, S., Thongsri, T., Jongpiputvanich, K., Krittayaphong, R., for the COOL-AF Investigators Tags: Open access, Cardiovascular medicine Source Type: research

Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol
Introduction The burden of atrial fibrillation (AF) in Thailand is high and associated with increased morbidity, mortality and healthcare costs. Vitamin K antagonists (eg, warfarin), commonly used for stroke prevention in patients with AF in Thailand, are effective but are often suboptimally controlled. We aim to evaluate the impact of an SAMe-TT2R2 score-guided strategy and educational intervention compared to usual care on anticoagulation control expressed by the time in therapeutic range (TTR) at 12 months, in anticoagulant-naïve Thai patients with AF. Methods and analysis Multicentre, open-label, parallel-grou...
Source: BMJ Open - October 11, 2021 Category: General Medicine Authors: Phrommintikul, A., Nathisuwan, S., Gunaparn, S., Krittayaphong, R., Wongcharoen, W., Sehmi, S., Mehta, S., Winkles, N., Brocklehurst, P., Mathers, J., Jowett, S., Jolly, K., Lane, D., Thomas, G. N., Lip, G. Y. H., TREATS-AF Study Group, Prasertwitayakij, Tags: Open access, Medical management Source Type: research

Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and chronic kidney disease in Asian Population,Data from the COOL-AF Thailand registry
Patients with AF and chronic kidney disease(CKD) encountered increased risks of stroke, bleeding, morbidity, and overall mortality. Oral anticoagulation in these populations definitely enhances major bleeding but the benefit of stroke reduction remained inconclusive.The aim of this study is to evaluate the effect of oral anticoagulation (OAC) on the 2-year cardiovascular outcomes in patients with AF and CKD .
Source: International Journal of Cardiology - August 19, 2020 Category: Cardiology Authors: Thoranis Chantrarat, Rungroj Krittayaphong Source Type: research

Oral anticoagulant-associated bleeding requiring hospitalization in Thai patients: Incidences, risk factors, and outcomes
Oral anticoagulants have been widely used in patients with atrial fibrillation (AF), mechanical valve and in the treatment of both arterial and venous thromboembolism (VTE). Warfarin is the conventional oral anticoagulant which was established its efficacy and safety profiles. Direct oral anticoagulants (DOACs) including dabigatran, rivaroxaban, and apixaban, have gained their popularity and been increasingly used since their approval in Thailand for stroke prevention in AF and VTE treatment.
Source: Thrombosis Research - September 4, 2019 Category: Hematology Authors: Kochawan Boonyawat, Patratorn Kunakorntham, Pantep Angchaisuksiri Tags: Letter to the Editors-in-Chief Source Type: research

Factors associated with low health-related quality of life among younger and older Thai patients with non-valvular atrial fibrillation
ConclusionsBleeding history and taking warfarin among younger patients, and ischemic stroke/TIA, HF, and dementia among older patients are significant predictors of low HRQoL. These factors should be taken into consideration when selecting treatment options for patients with NVAF.
Source: Quality of Life Research - April 4, 2019 Category: Health Management Source Type: research

Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
ConclusionsFor both societal and payer perspectives, high-dose edoxaban with a price below the country cost-effectiveness threshold should be the first anticoagulant option for Thai patients with non-valvular atrial fibrillation and a high risk of bleeding.
Source: PharmacoEconomics - November 2, 2018 Category: Health Management Source Type: research